LifeMine Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$120M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • LifeMine Therapeutics's estimated annual revenue is currently $27.7M per year.(i)
  • LifeMine Therapeutics received $55.0M in venture funding in September 2017.
  • LifeMine Therapeutics's estimated revenue per employee is $193,750
  • LifeMine Therapeutics's total funding is $120M.

Employee Data

  • LifeMine Therapeutics has 143 Employees.(i)
  • LifeMine Therapeutics grew their employee count by 7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$109.4M70614%N/AN/A
#9
$6.2M40233%N/AN/A
#10
$1.9M12-20%N/AN/A

LifeMine Therapeutics is pioneering a genomically-enabled drug discovery approach integrating advanced life science and computational technologies to elucidate human biology and create sophisticated therapeutics that attack the fundamental drivers of serious human diseases. LifeMine will access new drug modalities by conducting the first industrial-scale operation exploiting small molecule evolution in fungi to discover game-changing therapeutics. The initial focus will be on immune modulators, metabolic effectors, and cell differentiators. This platform is expected to provide multiple first- and best-in-class therapeutics in succession, and to continue delivering these for years to come. Founder & CEO: Greg Verdine, Erving Professor at Harvard University and Harvard Medical School. Founder of Gloucester Pharmaceuticals (acquired by Celgene), Enanta Pharmaceuticals (NASDAQ: ENTA), Eleven Biotherapeutics (NASDAQ: EBIO), Tokai Pharmaceuticals (NASDAQ: TKAI), WaVe Life Sciences (NASDAQ: WVE), Warp Drive Bio, Aileron Therapeutics, and the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy.

keywords:N/A

$120M

Total Funding

143

Number of Employees

$27.7M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

LifeMine Therapeutics News

2022-03-22 - LifeMine Therapeutics Announces $175 Million Series C ...

LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere. Through its...

2022-03-22 - LifeMine locks down $70M 'dream scenario' fungi partnership ...

The deal also includes undisclosed milestones and royalties. Greg Verdine LifeMine FOG Pharma. Gregory Verdine, Ph.D. (LifeMine Therapeutics).

2022-03-22 - GSK joins LifeMine's $175M funding, reviving fungi as a drug ...

LifeMine Therapeutics, a company that analyzes fungal genomes to find molecules that have potential as new medicines, has raised $175 million in...

2021-01-07 - LifeMine Therapeutics Announces $50 Million Series B Financing

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced a $50 million Series B financing from leading life sciences investors. The financing was led by Rick Kl ...

2021-01-07 - LifeMine Therapeutics Raises $50 Million Series B

CAMBRIDGE, Mass.--(BUSINESS WIRE)--LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced a $50 million Series B financing from leading life sciences investor ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$27.7M14312%$301.6M
#2
$15M14410%N/A
#3
$27.9M144-26%$367M
#4
$28.1M14525%$173M
#5
$32.2M14531%N/A

LifeMine Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-09-19$55.0MAWuXi Healthcare VenturesArticle